How would you treat high risk prostate adenocarcinoma who relapsed after RT and ADT with a very low PSA, widespread mets to bone and soft tissue who is progressing on ADT, docetaxel and carboplatin?
No targetable mutations detected
Answer from: Medical Oncologist at Community Practice
Difficult situation, this patient likely has neuroendocrine differentiation. I would check for markers like NSE, chromogranin if positive, then can make the case of treating as small cell ca progressed on platinum based chemotherapy and treat with lurbinectedin (Trigo et al., PMID 32224306).PSMA bas...
Comments
Medical Oncologist at Northwestern University I generally agree with the concern for neuro endoc...
I generally agree with the concern for neuro endoc...